Methods of treating psoriasis with secukinumab
Grant
US12594332B2
Kind: B2
Apr 07, 2026
Assignee
NOVARTIS AG
Inventors
Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
Abstract
The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
CPC Classifications
A61K 39/3955
A61K 2039/505
A61P 17/06
Filing Date
2024-12-16
Application No.
18983037
Claims
11